© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Atovaquone started out as a rescue project for people on the edge of tough infections. Back in the 1980s, big pharmaceutical companies were digging for a molecule that could help immunocompromised patients, especially those with HIV/AIDS who faced life-threatening pneumonia from Pneumocystis jirovecii. Scientists wanted an alternative to drugs riddled with heavy side effects. After years of digging through thousands of molecular structures, researchers landed on Atovaquone—something originally studied as a potential anti-malarial agent. Development ramped up fast once signs of efficacy against protozoal and fungal pathogens became evident. Clinical trials through the 1990s built its reputation as a kinder option compared to some staples of the infectious disease world.
Atovaquone today falls under the category of antiprotozoal agents. Pharmacies often carry it as an oral suspension or as part of a fixed-dose combination with proguanil for malaria prevention and therapy. Care teams reach for it when classic treatments like trimethoprim-sulfamethoxazole cause more trouble than they solve. It holds a special spot for people allergic to sulfa-based drugs or those dealing with complex coinfections. Prescribers appreciate the relatively gentle side effect profile, which avoids some of the grim consequences associated with traditional therapies for opportunistic infections or malaria.
Atovaquone’s crystal-clear red-brown powder, insoluble in water, tells a bit about its persistence and challenges with absorption. With a molecular formula of C22H19ClO3 and a molecular weight closing in on 366, the compound features aromatic rings and a chlorine atom, which influence its metabolic fate and interaction with biological membranes. Low water solubility means drug manufacturers must use creative technologies—think micronization and formulation with fats—to help the body absorb a meaningful dose. Under standard conditions, it holds up well in the container, asking for basic precautions against heat and sunlight.
Manufacturers produce Atovaquone in strict accordance with pharmacopoeial requirements. A typical oral suspension delivers doses at 750 mg per 5 mL, verified by methods like high-performance liquid chromatography. Specifications on microbial limits, identity, purity, and residual solvents reflect the expectations of both FDA and EMA guidelines. Product labeling details necessary storage conditions—between 15°C and 30°C and protected from light. Packaging carries information on expiration, batch number, and certifications. Pharmaceutical-grade producers test vulnerability to degradation under humidity or temperature spikes and provide instructions against accidental freezing or contamination.
Synthesis of Atovaquone generally relies on a multi-stage process. Chemists usually start from 2-chlorobenzoic acid, building up the naphthoquinone frame with a series of directed substitutions, condensations, and aromatic coupling steps. Controlling the formation of by-products like isomers or chlorinated derivatives takes rigorous process engineering. Isolation and purification often depend on crystallization methods, with analytical testing closing the loop to verify chemical identity and purity. Regulatory filings show a preference for solvent systems and reaction conditions that limit environmental risk and operator exposure.
Atovaquone’s core structure provides stable aromatic character, resisting random breakdown in the bloodstream. Structural modifications mostly aim to tweak its solubility or enhance bioavailability, an area that gets plenty of attention from formulation scientists. Researchers have experimented with salt forms, prodrugs, and nanoscale dispersions, looking for quicker uptake or better delivery to target organs, especially the liver and lungs. Modifying the quinone ring or the alkyl side chain carries a risk of diminishing the molecule’s antiprotozoal activity, so most successful strategies focus on formulation rather than major structural changes.
Atovaquone carries a cluster of chemical names, including trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone. The market knows it under the brand name Mepron for the oral suspension, and as part of Malarone when combined with proguanil hydrochloride. These combinations hit pharmacy shelves in international markets, sometimes under other trade names. References in scientific literature stick to the IUPAC or generic name, which helps avoid confusion for prescribers and regulators tracking usage and adverse events.
Handling Atovaquone on the factory floor or in a compounding lab calls for basic chemical hygiene. Direct skin or eye contact deserves proper protection, mostly because of its greasy, staining nature and unknown risks with repeated exposure. Regulatory agencies demand well-ventilated workspaces, regular air monitoring, and waste protocols to avoid contamination. Producers document cleaning procedures, equipment checks, and cross-contamination safeguards, especially when operating lines switch between pediatric and adult formulations. Workers undergo annual training, and safety data sheets cover chemical spill and first-aid responses in detail.
Immunologists and infectious disease specialists reach for Atovaquone most often in cases of Pneumocystis pneumonia for HIV/AIDS patients or cancer patients whose immune systems run thin. The medicine’s profile gained even more appreciation in regions battling malaria, where it forms the backbone of therapy for travelers and residents alike. Physicians extend its use to toxoplasmosis, babesiosis, and even some rare fungal infections, adjusting doses and duration based on clinical response and the nature of the pathogen. Besides routine hospital settings, tropical disease clinics and military health operations depend on formulations that travel well and retain potency under tough conditions.
Ongoing research circles around Atovaquone for new reasons beyond traditional infectious disease. Studies published in journals like Nature and The Lancet dive into its mitochondrial mechanism, suggesting the molecule holds promise against some cancers that rely on similar cellular machinery to parasites. Other groups aim to tweak Atovaquone’s formulation, looking for nanoparticles or co-milled powders that make oral dosing more reliable and less prone to erratic absorption. Academic-industry partnerships share data on resistance mechanisms, charting new paths to sidestep the loss of effectiveness that shadows most anti-infectives over time.
Long-term safety studies give Atovaquone a decent record, especially compared to harsher antiprotozoal drugs. Most complaints in trials center on stomach and gut symptoms, usually less severe than those seen with older sulfones or antibiotics targeting the same bugs. Preclinical work in animals at high doses provides no strong evidence for genetic damage or birth defects, and data on carcinogenicity falls well within comfort zones for both regulators and clinicians. Monitoring for rare reactions, like liver irritation or skin rashes, shapes ongoing pharmacovigilance programs. Studies in special populations—children, pregnant individuals, those with severe liver disease—fill in remaining safety gaps but always generate fresh questions for further research.
The search for new uses gives Atovaquone a longer shelf-life than many would have predicted even a decade ago. Innovation in drug delivery—think injectable or transdermal routes—could make it a mainstay for more systemic infections or for people unable to swallow reliably. As resistance to traditional antimalarials creeps up, public health organizations revisit Atovaquone-based regimens for mass campaigns. The drug’s mitochondrial target means interest continues for rare parasitic diseases as well as tough-to-treat cancers. Investment in basic science and translational studies holds the key. The next breakthroughs could easily arise from collaborations between international agencies, biotechs, and research hospitals answering the evolving threats of infectious and chronic disease.
Atovaquone plays a big role in the fight against certain infections that don’t have easy fixes. Most people find out about it when they or someone they know faces a disease that standard antibiotics can’t handle. Doctors often turn to this medicine for pneumocystis pneumonia (PCP). This infection hits people whose immune systems don’t keep up, often because of HIV/AIDS or cancer treatments. Without strong defenses, even bugs that most folks beat on a daily basis can take over. Atovaquone acts as one of the front-line options for these tough cases, giving folks a chance when many drugs fall short.
Travelers to places where malaria still rages know atovaquone from the pill packs that come before a flight. Combination medicines using atovaquone, like atovaquone-proguanil (sometimes called by the brand name Malarone), help keep malaria-causing parasites from hijacking your red blood cells. Malaria still kills around 600,000 people every year worldwide, making reliable protection a must for anyone going to high-risk regions. If you’ve ever been worried about picking up a serious illness on the other side of the world, atovaquone stands as a simple, science-backed layer of protection.
Older medicines for PCP and malaria often come with nasty side effects or growing drug resistance. Take treatment for PCP — some people react badly to the usual drugs like trimethoprim-sulfamethoxazole, ending up with rashes or other problems tough to ignore. Atovaquone usually goes down easier, which means patients stick with the plan and see the infection clear up. For malaria, more stories of parasite resistance show up each year. Using newer combinations with atovaquone helps slow that tide, which means fewer relapses and better odds for everyone involved.
One problem that stands out about atovaquone is the cost. Many newer antimicrobials hit insurance rules or high out-of-pocket prices, especially in developing countries where malaria rates skyrocket. During my time working with clinics overseas, I saw the real frustration when families couldn’t afford recommended medicines. Finding generic versions and pushing health systems to support these medications matters as much as any lab result or doctor’s note. Usually, life-saving treatments need to reach beyond the people who live in rich countries.
Another issue centers on parasite resistance. Like any tool, atovaquone works best when used carefully. Too many shortcuts in prescribing and over-the-counter sales can help parasites adapt to the medicine, making it useless in the areas that need it most. A strong commitment to proper diagnosis and prescription, especially in malaria-endemic regions, counts far more than any single breakthrough drug. Doctors I’ve met in community clinics always balance the need for quick fixes with the concern for what overuse might mean down the road.
Supporting the right use of atovaquone starts with education for both healthcare workers and the public. Programs that guide travel medicine, HIV care, and malaria prevention make a real difference. Investments from government and industry can drive down costs and increase availability so people in low-resource settings get the same chances as those elsewhere. Most importantly, keeping research going to track resistance and develop new combinations ensures this medicine keeps helping, long after today’s challenges pass.
Atovaquone shows up most often in the conversations of people bitten by mosquitoes traveling in regions where malaria still stands as a serious threat. Doctors prescribe it along with proguanil as a preventative step. Atovaquone also comes into play for those fighting against certain types of pneumonia, especially in folks with immune systems that need extra help. These uses help explain why understanding the possible drawbacks of the medication matters to many people.
Stomach issues often find their way into daily life for people taking atovaquone. I remember meeting travelers in a Bangkok hostel, passing around water bottles and anti-malarials. The shared complaints usually started with nausea or that uneasy, sour feeling in the gut. Diarrhea came up so often it became a running joke on long bus rides. People rarely talk about the subtle things — the way food seems less appealing, or that odd taste that lingers in the mouth — but these effects can make someone avoid meals or feel a bit off balance. That ‘bad taste’ crops up more often than you might expect, reported by enough patients that it made its way into the official literature on the drug.
Fatigue sometimes creeps in and hangs around. I’ve heard from pharmacists and clinicians alike that patients show up asking about odd, lingering tiredness, and wonder if it’s the price of protection against something much worse. Dizziness can join the fatigue, sometimes making a busy day tougher to manage. These side effects rarely drum up emergencies, but they can slow people down or give them second thoughts about taking their meds.
Doctors keep an eye out for signs of allergic reactions, though these remain pretty rare. Itching, rash, and swelling fit into this category and call for medical attention. The liver works hard to filter out anything we put in our bodies, and atovaquone is no exception. Some people might see signs that their liver is under stress — dark urine, yellowing of the skin or eyes. Healthcare workers test for changes in liver function for good reason.
Published clinical studies in journals like Clinical Infectious Diseases and information from the Food and Drug Administration list nausea and diarrhea as the most common complaints. Less often, headaches and fever sneak into the picture. A wide review of patient experiences recorded headache in about 13% of people using the drug. Numbers matter, but the lived experiences of patients — from travel forums to conversations with nurses — paint a full picture.
Doctors and pharmacists offer advice that ranges from taking pills with food to minimizing nausea, to staying hydrated and getting plenty of rest. Anyone who starts to feel seriously unwell — especially with signs of allergic reaction or liver trouble — should speak up right away. It helps to keep an open line with medical providers, describing all symptoms honestly, even those that might seem minor. Reporting side effects to the health care team makes a real difference, both for the individual and for future patients.
Staying healthy sometimes asks for trade-offs. Atovaquone helps knock out serious threats, and knowing what to expect can help you handle side effects better. Listening to the stories of those who’ve taken this medication, backed up by careful clinical observation, gives us a clearer sense of what to watch for, and what steps bring relief.
For those dealing with certain infections, especially for folks with weakened immune systems, Atovaquone stands out as a crucial medication. Commonly prescribed to prevent or treat Pneumocystis jiroveci pneumonia (PJP), toxoplasmosis, or babesiosis, it often brings real relief. The thing about Atovaquone is, it only works its magic when taken the right way—paying attention to dosing and food matters a lot.
Doctors usually recommend taking Atovaquone with food. A meal that includes some fat—like eggs, cheese, peanut butter, or whole milk—can make a big difference. Fat helps the body absorb the medicine better, so it reaches the infection site at the amounts your doctor wants. People who take it on an empty stomach usually don’t get as much benefit; studies have shown the drug level in the blood drops without enough food, slashing its ability to fight off infections. Atovaquone comes as a liquid, which might seem unusual for adults, but using an oral dosing syringe helps measure the amount accurately. Shaking the bottle before pouring keeps the medicine mixed and even.
Building Atovaquone into a daily routine helps cut down on missed doses. Checking off doses on a calendar or setting a phone reminder works for lots of people, especially those juggling different medications. If a dose gets missed, it’s best to take it as soon as it’s remembered—unless it’s almost time for the next one. Doubling up can cause trouble, so it’s smart to stick with the regular amount. Symptoms returning or not improving, even with full courses, always deserve a call to the healthcare provider.
Atovaquone can upset the stomach or cause nausea, but sticking to the “with food” rule eases most of the trouble. Diarrhea can happen, but staying hydrated helps. Some people may see a rash or notice a change in taste. Keeping the doctor updated, especially if side effects hang around, leads to better adjustments or alternatives.
Buying Atovaquone through a licensed pharmacy protects against counterfeit medications. If the price feels too high, it's worth asking about generic options or patient assistance programs. Checking the expiration date before every use keeps the medicine working as expected. Storing the bottle at room temperature—away from sunlight and out of reach of children—also matters.
Real-world experience points to better results when patients share everything—current medicines, vitamins, even herbal teas. Atovaquone’s effects can change if mixed with certain drugs. Open conversations lead to safer care and help avoid rare reactions. If a person vomits soon after taking their dose, doctors sometimes suggest repeating the dose or checking blood levels, so nothing slips through the cracks.
Helping friends or family members manage complex regimens like Atovaquone can lift a load. Getting facts from reliable places like the CDC or Mayo Clinic, and leaning on pharmacists for quick questions, empowers everyone involved. Staying informed, prepared, and in touch with the care team makes all the difference in recovering and staying well.
Being pregnant or breastfeeding brings a constant stream of questions and concerns. Every meal, over-the-counter medicine, and supplement sparks worry about what’s safe and what’s risky. If a doctor mentions a drug like atovaquone, nerves often sharpen even more. I remember the round-the-clock anxieties when my own family needed to treat illness during pregnancy, and we scrambled for reliable information. That feeling of searching for solid answers is common for many parents.
Atovaquone helps treat infections like malaria and Pneumocystis pneumonia. Over the years, it’s saved lives for people with weak immune systems or those traveling to malaria-prone regions. Doctors trust its power, but its safety in pregnancy and while breastfeeding isn’t a settled matter.
Small studies and animal research don’t turn up evidence of birth defects or dangerous effects on nursing babies. Yet, big, long-term studies with pregnant people haven't been completed. That gap leaves families and doctors making decisions with limited data. It’s similar to situations with other medications for HIV or severe infections — sometimes, the immediate benefit outweighs the unknown risks. Parents face tough choices, and healthcare teams have to consider each case’s details instead of relying on black-and-white answers.
Pregnancy doesn’t press pause on serious illness. Malaria in pregnancy, for example, brings risks for moms and babies: miscarriage, low birth weight, and maternal complications. Pneumonia can turn dangerous without the right treatment. If atovaquone gives someone the best shot at recovery, it’s hard to ignore the benefit, even if some questions still linger.
So far, the U.S. Centers for Disease Control and Prevention (CDC) and organizations like the World Health Organization treat atovaquone as an option when safer drugs don’t work or can’t be used. Doctors often use it with proguanil during pregnancy if no better choice exists. It’s not a go-to medicine, probably because drug companies and health agencies hesitate to clear medicine for broad use in mothers without stronger proof of safety. If a pediatrician or infectious disease specialist recommends atovaquone, they’re likely considering all options — not defaulting to a risky bet.
When nursing, mothers worry about even tiny exposures reaching their baby’s system. The limited research suggests that babies get very little atovaquone through breast milk, and no worrisome effects have been reported. That said, experts still recommend keeping an open conversation with doctors. The American Academy of Pediatrics rates atovaquone as “probably compatible” with breastfeeding, but careful thought goes into that call. If a mom or her baby has another illness or takes other medication, the team checks for unexpected drug interactions.
No parent wants to play guessing games with medication safety. Access to real-world experience from providers, clear communication, and trustworthy fact sheets matter most. Some hospitals offer maternal-fetal specialists who dig into available research and connect patients with pharmacists trained in medication safety.
Pushing for better studies and more transparency serves families best in the long run. Until research catches up, parents and doctors can rely on thoughtful risk assessment, current evidence, and honest discussions. In my experience, asking questions and seeking second opinions don’t just ease worry — they help families stand strong during uncertain times.
Starting a medicine like atovaquone usually follows a chat with a doctor. Many folks skip asking about food or other drug clashes, but that’s where trouble can sneak up on you. I’ve seen cases where careful folks land in the ER because of a grapefruit or a pill they thought was harmless. With atovaquone, this isn’t far-fetched.
Taking atovaquone with rifampin or rifabutin can tank its levels in the blood. These antibiotics help treat infections like tuberculosis, but they push atovaquone right out of your system before it has a chance to work. I’ve seen the frustration on faces of people who thought they were fighting their infection, only to learn the drugs were fighting each other instead. When antibiotics are on the table, always double-check the list. It saves time, money, and a scary hospitalization.
Carbamazepine and phenytoin, both seizure medications, tell a similar story. They rev up the body’s drug-cleaning engines, cutting atovaquone’s effectiveness in half, sometimes more. I once met someone whose malaria treatment failed after they started a new seizure pill. If a person needs these medications to control seizures, the prescriber should be in the loop to adjust doses, or maybe pick a different malaria prophylaxis altogether.
Some people take blood thinners like warfarin. Atovaquone can raise warfarin’s effect, tipping the balance toward dangerous bleeding. Bleeding gums or unexpected bruises point to trouble. Doctors often follow this with extra blood tests to adjust the warfarin. Nobody likes more needle pokes, but a clot or a hemorrhage causes bigger problems.
Swallowing atovaquone on an empty stomach slices its absorption. People who rush in the morning or can’t stomach food might waste a costly drug by just taking it with water. Fat in a meal cranks up how much atovaquone the body pulls in. Eating something rich—avocado, peanut butter, or a bit of cheese—can make a difference between getting better or ending up stuck on meds for longer. I’ve worked with people whose stomach just couldn’t handle greasy food, so we found creative solutions like yogurt or a milkshake instead. Skipping the meal means less drug does its job.
In pharmacies, grapefruit almost always gets flagged. Grapefruit can rev up or slow down enzymes in the liver needed for breaking down drugs. While grapefruit’s impact on atovaquone looks less clear than on cholesterol drugs (like statins), the possible effect isn’t zero. Most experts say to avoid mixing them, just to play it safe—the mess isn’t worth it, especially for people already dealing with illness.
Herbal supplements like St. John’s Wort speed up drug breakdown, tossing atovaquone right out along with the other affected medicines. People often start St. John’s Wort for mood without any clue about the clash. I urge anyone eyeing a new supplement to crosscheck with their pharmacist.
People shouldn’t have to guess if a salad or new vitamin will cancel out their treatment. Doctors and pharmacists carry that responsibility, but patients play a part too. Bring every bottle—prescription and over-the-counter—when seeing your provider. Share your daily routine and let the medical team help spot interactions. Real health comes from the tiny details, and catching an interaction early means better odds of getting well with fewer surprises.
| Names | |
| Other names |
Mepron Wellvone |
| Pronunciation | /əˌtoʊvəˈkwoʊn/ |
| Identifiers | |
| CAS Number | 94025-53-9 |
| Beilstein Reference | 3831426 |
| ChEBI | CHEBI:63922 |
| ChEMBL | CHEMBL944 |
| ChemSpider | 5127 |
| DrugBank | DB01117 |
| ECHA InfoCard | echa infocard 100948 |
| EC Number | EC 1.10.3.8 |
| Gmelin Reference | 115282 |
| KEGG | C07656 |
| MeSH | D019844 |
| PubChem CID | 74989 |
| RTECS number | RG9350000 |
| UNII | 6RYC6M3US5 |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | urn:epacontoxdashboard:DTXSID7020981 |
| Properties | |
| Chemical formula | C22H19ClO3 |
| Molar mass | 366.840 g/mol |
| Appearance | Yellow crystalline powder |
| Odor | Odorless |
| Density | 1.3 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 4.7 |
| Vapor pressure | 9.94E-16 mmHg at 25°C |
| Acidity (pKa) | 6.9 |
| Basicity (pKb) | 15.66 |
| Magnetic susceptibility (χ) | -74.0e-6 cm^3/mol |
| Refractive index (nD) | 1.650 |
| Viscosity | Viscosity: "DMSO c=10mg/mL: <0.409 |
| Dipole moment | 6.4474 D |
| Thermochemistry | |
| Std enthalpy of formation (ΔfH⦵298) | -835.2 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -8154 kJ/mol |
| Pharmacology | |
| ATC code | J01AX07 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS labelling of Atovaquone: "Warning; H302; H315; H319; H335 |
| Pictograms | medicines.svg|oral-use.svg|prescription-only.svg |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | P264, P270, P280, P301+P312, P330, P501 |
| Flash point | 120.2 °C |
| Lethal dose or concentration | LD50 (rat, oral): >5000 mg/kg |
| LD50 (median dose) | LD50 (median dose): >5 g/kg (oral, rat) |
| NIOSH | Not Listed |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 750 mg PO q12h |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Atovaquone/proguanil Lapachol Menadione |
